For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and ...

Reports Q4 revenue $35.69M. “With continued advancements across our commercial and clinical portfolio, CRISPR Therapeutics (CRSP) is poised to ...

A new UCLA Health study has discovered in mouse models that genes associated with repairing mismatched DNA are critical in ...

Using CRISPR technology, scientists uncovered genes that control C-A-G genetic stumbles in Huntington's disease ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...